Facebook
Twitter
LinkedIn
ForwardWebcast - Molecular-Targeted Therapies in Lung Cancer: Practical Application of Clinical Trials Data
This accredited continuing education activity “Webcast-Molecular-Targeted Therapies in Lung Cancer: Practical applications of clinical trials data," is recorded from the live oncology webinar held on 7/10/2021.
If you participated in the live webinar titled - Molecular-Targeted Therapies in Lung Cancer: Practical applications of clinical trials data on 7/10/2021 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 7/10/2021. However, you may enroll in this activity to review the contents.
The recorded lectures and subsequent discussions feature leading experts in lung cancer who provide a comprehensive overview of implications of actionable molecular alterations in lung cancer.
The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for their patients with lung cancer. This program features in-depth discussions and analysis of the latest scientific findings and practice-changing advances (including the data presented at the 2021 ASCO Annual Meeting in June, 2021) in molecular testing and targeted-therapies for lung cancer. Expert faculty will utilize didactics, case-based presentations and related panel discussions, and aim to place molecular testing into clinical context and discuss how the results may effectively contribute to patient care.
This educational activity will augment healthcare providers’ foundation of knowledge and clinical competence in several areas, including:
- Role of different platforms, including next generation sequencing, in testing for actionable molecular alterations to identify targeted therapy options in lung cancer.
- Current and evolving paradigms in a biomarker driven precision oncology approach for management of lung cancer.
- Trends, challenges, controversies, and limitations of precision oncology approaches and targeted therapies in management of lung cancer.
REGISTRATION FEES:
This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0.
Healthcare providers ($0.00)
Industry employees ($200 + 3% Credit card fee)
If you are a healthcare provider involved in patient care and you are not employed by the Industry, please register for the course here
If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.
If you paid to join the live meeting and wish to register for this enduring material please contact us and we will register you for free.
Target Audience
- Oncologists
- Oncology Nurse Practitioners & Physician Assistants
- Oncology Pharmacists
- Oncology Nurses
- Residents/Fellow
- Researchers
Learning Objectives
Upon successful completion of this educational activity, participants will be able to:
- Review the role, including advantages and disadvantages, of different testing methodologies available for detecting molecular alterations in lung cancer.
- Interpret results of next generation sequencing and other biomarkers predictive of response to targeted therapies in lung cancer.
- Plan optimal molecular-targeted adjuvant and/or extended adjuvant strategies for patients with non-metastatic NSCLC.
- Integrate recent advances and available clinical data to optimally sequence molecular-targeted agents in the treatment of metastatic NSCLC.
- Outline emerging research, the mechanism of action, and the role of novel molecular-targeted therapies in clinical investigation for patients with NSCLC .
This educational activity features recorded videos from the live virtual meeting held on 7/9/21. The videos are placed in the following order. Feel free to view the content that is relevant to you. Participants should claim continuing education credits to the extent of their participation.
20 minutes - Epidemiology of molecular alterations in lung cancer - Dr. Christina Merkhofer
25 minutes - Methodologies for detection of molecular driver mutations in lung cancer, a case-based discussion - Dr. Tejas Patil
20 minutes - Session 1 Q&A
25 minutes - Molecular-guided adjuvant therapy for lung cancer - Dr. Rafael Santana-Davila
25 minutes - Molecular-guided therapy for metastatic lung cancer: Targeting EGFR, ROS1, ALK and BRAF – Dr. Kathryn Gold
20 minutes - Molecular-guided therapy for metastatic lung cancer: Targeting MET, NTRK and RET - Dr. Wade Thomas Iams
40 minutes - Emerging precision oncology approaches in management of lung cancer, a case-based discussion - Dr. Narjust Duma
30 minutes - Session 2 Q&A
| Narjust Duma, MDAssistant Professor of Medicine Dana-Farber Cancer Institute/Harvard University |  | Cristina Merkhofer, MDAssistant Professor of Medicine University of Washington Medical Oncologist Seattle Cancer Care Alliance |
 | Kathryn Gold, MDAssociate Professor of Medicine University of California, San Diego |  | Tejas Patil, MDAssistant Professor of Medicine University of Colorado |
 | Wade Iams, MDAssistant Professor of Medicine Vanderbilt University |  | Rafael Santana-Davila, MDAssociate Professor of Medicine University of Washington Medical Oncologist Seattle Cancer Care Alliance |
 | Kumar Prabhash, MDMedical Oncologist Tata Memorial Hospital, Mumbai, India |
DISCLOSURES
No Members of this activity's planning committee or faculty have any relevant financial relationship with an ineligible entity except for the following faculties:
- Dr. Kumar Prabhash: Research support/Grant - Roche, Alkem, Dr Reddys, Intas, Glenmark, Biocon
- Dr. Rafael Santana-Davila:
- Dr. Kathryn Gold: Consultant – AstraZeneca, Takeda, Rakuten; Research Support/Grant – Pfizer, Pharmacyclics
- Dr. Wade Iams: Speakers Bureau – Amgen; Consultant – Genentech, G1 Therapeutics, Mirati
- Dr. Narjust Duma: Consultant – Pfizer, AstraZeneca, Jansen, Neogenomics/Inivata,
All relevant financial relationships of individuals in control of the content have been identified and mitigated.
DISCUSSION OF OFF LABEL PRODUCTS
If any part of this activity will include the discussion of unapproved or investigational products, faculty discussing those products will clearly identify the product as investigational or not approved.
Important Information about Claiming CME for this activity:
If you participated in the live webinar titled - Molecular-Targeted Therapies in Lung Cancer: Practical applications of clinical trials data on 7/10/2021 and claimed CME credits/MOC points for that activity, you do not qualify for CME credits/MOC points for your participation in this enduring activity. This is a recorded content from that webinar on 7/10/2021. However, you can still enroll in this activity and review the contents as needed.
The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians.
The Binaytara Foundation designates this enduring activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria for up to 3.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
Nursing Contact Hours: Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 3.25 Contact Hours.
Acknowledgment of Commercial Support:
The live portion of this activity (live webinar held on 7/10/21), and all associated enduring activities, including this recorded webcast, are supported with an independent Medical Education Grant from Merck & Co.
Available Credit
- 3.25 AMA PRA Category 1 Credit™The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 3.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 3.25 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
- 0.00 Attendance
- 3.25 Nursing Contact HoursProvider approved by the California Board of Registered Nursing, Provider # CEP17035, for 3.25 Contact Hours.
Price
REGISTRATION FEES:
This activity is free for all healthcare providers who are not employees of an ineligible entity. Please select "non-industry learner" when you are ready to register for the course, and the price will reset to $0.
Healthcare providers ($0.00)
Industry employees ($200 + 3% Credit card fee)
If you are a healthcare provider involved in patient care and you are not employed by the Industry, register for free!
If you are employed by industry, you must pay a registration fee to participate in these meetings. Any unpaid industry registrations will be invoiced $412 per participant.
If you paid to join the live meeting and wish to register for this enduring material please contact us and we will register you for free.
Cancellation Policy
You may cancel your enrollment at any time. No credits will be offered if you do not complete all required steps of this activity which include registration, watching the recorded content, and completion of pre & post tests as well as course evaluations.
Refund Policy
This activity is free for all healthcare providers who are not employees of an ineligible entity.
No refunds will be issued if you have started watching the recorded content.